Clinical Research Industry Report

06

Top Firms

05

Top 20 Organizations Clinical Vacancies, Life Sciences Sector, Europe, 2021-2023*

Whilst the ongoing importance of the CROs in terms of the clinical function is clear, when analyzing activity by organization, it is not a surprise these are the businesses with some of the biggest drops in vacancies, year on year. Nonetheless, of the top five companies with clinical vacancies this year, four are CROs. With that, ones worth profiling include: • Syneos Health, which although it has had the highest annual totals is set to see a 42.6% year-on-year reduction in vacancies. • AstraZeneca is the leading Pharmaceutical company in terms of Clinical vacancies and has actually had a significant uplift in activity this year, with volumes up 45.7%. • PRA has had the steepest year-on-year decline in activity, with vacancies down 54% on last year. • In contrast, Pfizer is one to watch, with a year-on-year uplift of 127%, which is the largest increase out of any of the organizations in the top 20. • Novartis have also had a significant surge in activity this year, with vacancies up 78% on 2022. • Within the top ten organizations, Merck has seen the biggest increase, with vacancies up 66% on last year. In summary, eleven of the top twenty organisations have seen a decline in clinical vacancies, equally when we remove the CROs from that, we see that it is only six out of fifteen. Put another way, 60% of the pharmaceutical companies have seen an uplift this year compared to last which suggests that as the number of trials has slowed down, they have just decided to do more in-house and outsource less. Equally given what we discussed earlier, in terms of the regulators getting up to date with their backlogs of trial requests, we expect next year to be a busy one all round.

YoY%

Organization

2021 2022 2023*

-42.6%

Syneos Health

1528

1854

3230

-9.8%

Iqvia

1239

832

922

45.7%

AstraZeneca

524

397

360

-54.1%

PRA Health Sciences

422

1130

920

-44.4%

ICON

396

625

712

Parexel Labcorp Drug Development Novo Nordisk

-4.1%

367

617

383

-38.7%

322

798

525

16.0%

311

210

268

Merck

66.4%

228

121

137

GSK

-9.9%

181

207

201

Medpace

1.1%

154

121

152

Lilly

41.9%

88

132

93

Cromsource

-7.8%

124

161

134

Novartis

78.2%

118

86

66

-19.4%

Cmed

23

108

134

127.0%

Pfizer

104

87

46

-67.8%

Johnson & Johnson

198

67

209

22.8%

129

53

43

AbbVie

-49.0%

90

41

80

Roche

-64.5%

35

151

98

Bristol-Myers Squibb

Source: Vacancysoft Analytics

Fig. 07

2023* - Estimation

Made with FlippingBook - professional solution for displaying marketing and sales documents online